Meeting
2019 ASCO Annual Meeting
Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.
Authors
Xiang Guo
MedImmune, Gaithersburg, MD
Xiang Guo , Brandon W. Higgs , Paul Baverel , Jean Fan , Nassim Morsli , Magdalena Wrona , Alejandro Javier Yovine , Shao-Chun Chang , Rosalin Arends , Lorin Roskos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02207530; NCT02319044
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6048)
DOI
10.1200/JCO.2019.37.15_suppl.6048
Abstract #
6048
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2015 ASCO Annual Meeting
A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).
First Author: Dan Paul Zandberg
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2023 ASCO Annual Meeting
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
First Author: Ezra E.W. Cohen